Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEKTAR THERAPEUTICS

(NKTR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nektar Therapeutics : Corporate Presentation September 2021

09/17/2021 | 08:12pm EST

Nektar Therapeutics Corporate Presentation

September 2021

This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data.Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings with the SEC including the Form 10-Q filed on August 6, 2021.Nektar undertakes no obligation to update forward-looking statements as a result of new information or otherwise.

2

Nektar is Developing Innovative Medicines for Patients with Cancer and Autoimmune Diseases

Program

Indication

Study

Preclinical

Phase 1

Phase 2

Phase 3

Metastatic Melanoma

BEMPEG + OPDIVO® vs. OPDIVO®

Registrational Study

Renal Cell Carcinoma

BEMPEG + OPDIVO® vs. TKI

Registrational Study

Muscle-invasive Bladder Cancer

BEMPEG + OPDIVO® vs. OPDIVO®

Registrational Study

Bempegaldesleukin

Adjuvant Melanoma

BEMPEG + OPDIVO® vs. OPDIVO®

Registrational Study

(BEMPEG)

Bladder Cancer

BEMPEG + OPDIVO®

AA Registrational Study

(NKTR-214)

Head & Neck SCC

BEMPEG + KEYTRUDA®

Phase 2/3

Immuno-

Renal Cell Carcinoma

BEMPEG + OPDIVO® + TKI

Phase 1/2

1L NSCLC

BEMPEG + KEYTRUDA®

Phase 1/2

oncology

Head & Neck SCC

BEMPEG + VB10.NEO

Phase 1/2a

NKTR-262

Multiple Solid Tumors

NKTR-262 + BEMPEG

Phase 1/2

R/R NHL or Multiple Myeloma

NKTR-255 + RITUXAN® or DARZALEX FASPRO®

Phase 1/2

Head & Neck and Colorectal

NKTR-255 + ERBITUX®

Phase 1/2

NKTR-255

ALL & DLBCL

NKTR-255 + CD19/22 CAR T-cell

Phase 1

DLBCL

NKTR-255 + Liso-cel

Phase 1

Systemic Lupus Erythematosus

LY3471851 / NKTR-358

Phase 2

Immunology

Ulcerative Colitis

LY3471851 / NKTR-358

Phase 2

LY3471851 / NKTR-358

Psoriasis

LY3471851 / NKTR-358

Phase 1b

Atopic Dermatitis

LY3471851 / NKTR-358

Phase 1b

Virology

BEMPEG

COVID-19

BEMPEG

Phase 1

NKTR-255

Virology

NKTR-255

Opdivo is a registered trademark of Bristol-Myers Squibb Company; Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.; Rituxan is a registered trademark of Biogen; Darzalex Faspro is a registered trademark of Janssen Biotech, Inc.; Erbitux is a registered trademark of ImClone LLC., a subsidiary of Eli Lilly & Co.; AA: Accelerated Approval

|

3

Nektar is Leading the Development of Cytokine-Based Therapies

IL-2

IL-15

IL-2

beta

(CD25)

gamma

Immune

Activation

alpha

(CD122)

(CD132)

Dimeric IL-2R

IL-2

IL-2 Receptor (IL-2R)

subunits Immune

Regulation

Trimeric IL-2R

IL-15Rα

Immune

Stimulation

IL-15

BEMPEG (CD122-BiasedIL-2 Pathway Agonist)

Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs), Increase PD-1 expression

NKTR-358(IL-2 Pathway Conjugate)

A conjugated IL-2 agonist biased for T regulatory cell expansion

NKTR-255(IL-15 Receptor Agonist)

Stimulate and expand NK Cells & Promote survival and expansion of memory CD8+ T cells

4

Capturing the Potential of the IL-2 Pathway in Immuno-Oncology:

Bempegaldesleukin Designed to Stimulate T-Cell Proliferation

Bempegaldesleukin

IL-2 Receptor

IL-2 signaling

Cell activation & proliferation

Immune system stimulation

alpha

to IL-2Rbeta-gamma

beta

(CD25)

gamma

IL-2

(CD122)

(CD132)

Cytotoxic T cell

IL-2 Receptor

Dimeric IL-2R

Subunits

Natural Killer (NK) Cell

Tumor cell

  • Preferentially signals IL-2Rbeta-gamma complex to stimulate cytotoxic T cells
  • Retains some transient binding to the alpha receptor to enhance priming in lymph nodes
  • Prodrug design and receptor bias eliminate over-activation of IL-2 pathway
  • Achieves antibody-like dosing schedule in outpatient setting

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Nektar Therapeutics published this content on 18 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2021 00:11:08 UTC.


ę Publicnow 2021
All news about NEKTAR THERAPEUTICS
11/30Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Programs At th..
CI
11/15NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
PR
11/15Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainar..
CI
11/12Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at th..
PR
11/09Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cance..
PR
11/08Benchmark Upgrades Nektar Therapeutics to Buy From Hold; Price Target is $20
MT
11/05Nektar Therapeutics Q3 Loss Widens as Revenue Drops; Shares Slump 21%
MT
11/05Oppenheimer Adjusts Nektar Therapeutics PT to $21 From $25, Maintains Perform Rating
MT
11/05NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re..
AQ
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
More recommendations
Financials (USD)
Sales 2021 102 M - -
Net income 2021 -530 M - -
Net cash 2021 463 M - -
P/E ratio 2021 -3,86x
Yield 2021 -
Capitalization 2 067 M 2 067 M -
EV / Sales 2021 15,7x
EV / Sales 2022 5,79x
Nbr of Employees 718
Free-Float 99,3%
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 11,20 $
Average target price 26,31 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Howard W. Robin President, Chief Executive Officer & Director
Gilbert M. Labrucherie Chief Operating & Financial Officer
Robert B. Chess Chairman
Jonathan Zalevsky Chief Research & Development Officer
Dimitry S. A. Nuyten Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-34.12%2 067
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625